Cannabinoid Signaling

Overview

The endocannabinoid system (ECS) is a lipid-based signaling network that evolved hundreds of millions of years ago and has been repurposed by every vertebrate nervous system. Named after the plant Cannabis sativa — whose Δ9-THC was the first cannabinoid receptor ligand identified — the system is now understood as a modulator that "turns the volume up or down" on many other pathways rather than initiating them. It operates largely on demand: endocannabinoids are synthesized from membrane phospholipid precursors at the moment they are needed, signal locally, and are rapidly degraded.

For peptide researchers, cannabinoid signaling is relevant as a partner to neuropeptide systems — including opioid and melanocortin circuits — and as a modulator of GPCR signaling at synapses.

How It Works

Receptors

The two canonical cannabinoid receptors are both class A G-protein-coupled receptors:

• CB1 — the most abundant GPCR in the mammalian brain, concentrated on presynaptic terminals of GABAergic and glutamatergic neurons. Also present in peripheral nerves, adipose tissue, liver, and skeletal muscle.
• CB2 — predominantly immune and hematopoietic (microglia, macrophages, B cells), with emerging roles in bone, gut, and select neurons.

Both typically couple to Gi/o, inhibiting adenylyl cyclase and opening inwardly-rectifying potassium channels while closing voltage-gated calcium channels — reducing neurotransmitter release when activated presynaptically.

Beyond CB1/CB2, endocannabinoids and related lipids act on GPR55, GPR119, PPAR-α/γ, and the TRPV1 channel, broadening the ECS into the "endocannabinoidome."

Endocannabinoids

The two best-studied endocannabinoids are:

• Anandamide (N-arachidonoylethanolamine, AEA) — synthesized from N-acyl phosphatidylethanolamine by NAPE-PLD and degraded by fatty acid amide hydrolase (FAAH).
• 2-Arachidonoylglycerol (2-AG) — synthesized on demand from diacylglycerol by DAGL-α/β and degraded by monoacylglycerol lipase (MAGL).

Both are derived from arachidonic acid and, because they are lipid-soluble, are not stored in vesicles. They are produced in the postsynaptic neuron and travel backward across the synapse to engage presynaptic CB1 — the canonical retrograde signaling paradigm.

Downstream Effects

Beyond modulating neurotransmitter release through classical Gi/o effects, cannabinoid signaling activates the MAPK/ERK pathway, influences PI3K/Akt, modulates nitric oxide production in immune cells, and crosstalks with opioid receptors through heterodimerization.

Biological Roles

Neurotransmission and Plasticity

CB1-mediated retrograde signaling underlies several forms of short-term and long-term synaptic plasticity (depolarization-induced suppression of inhibition/excitation, eCB-LTD). This makes the ECS a central tuner of learning, memory, anxiety, and sensory processing.

Pain Modulation

CB1 and CB2 both contribute to analgesia — CB1 at spinal and supraspinal sites, CB2 peripherally on immune cells. The pathway overlaps extensively with the opioid receptor system.

Appetite and Metabolism

CB1 activation in hypothalamic and mesolimbic circuits promotes food intake, synergizing with ghrelin signaling and opposing leptin signaling. Peripheral CB1 activation in liver and adipose tissue favors lipogenesis and insulin resistance.

Immune Regulation

CB2 dampens pro-inflammatory cytokine production, shifts macrophage polarization, and influences leukocyte trafficking, positioning the ECS as an endogenous brake on inflammation that complements NF-κB regulation.

Reproduction, Stress, and Development

ECS activity in the hypothalamus interfaces with the HPA axis and HPG axis. Endocannabinoids play essential roles in implantation, neuronal migration, and axon guidance during development.

Relevance to Peptides

• Peptide modulators of cannabinoid receptors: hemopressin, a 9-amino-acid peptide derived from hemoglobin α-chain, is a negative allosteric modulator of CB1 — an early example of a "peptide cannabinoid."
• Crosstalk with neuropeptides: CB1 functionally interacts with opioid receptors, orexin receptors, oxytocin, and melanocortin MC4R in appetite and mood circuits.
• Peripheral peptide-cannabinoid dual therapies: combinations targeting GLP-1 (GLP-1 receptor signaling) plus peripheral CB1 are under study for obesity and metabolic disease.

Therapeutic Implications

Approved cannabinoid-based medicines include nabiximols and CBD (Epidiolex for certain epilepsies). Rimonabant, a CB1 inverse agonist briefly approved for obesity, was withdrawn over psychiatric adverse effects — a cautionary story about central CB1 blockade. Current development favors peripherally restricted CB1 antagonists, CB2 agonists for inflammation, FAAH/MAGL inhibitors, and allosteric modulators including peptide-derived compounds.

Current Questions

How to exploit CB2 selectivity for inflammation without CB1 psychoactive effects, how allosteric peptide modulators compare to orthosteric ligands in clinical contexts, and how the ECS coordinates with other lipid and peptide signaling systems during stress and disease remain active lines of research. Its relationship to apoptosis, autophagy, and cancer biology is also under close study.